Kamiya Mehla

Kamiya Mehla

Auto-generated profile, based on publicly available information

Kamiya Mehla

The Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Trends in Cancer
Verified
Journal Article
Closed access
KMKamiya Mehla
Kamiya Mehla
PSPankaj Singh
Pankaj Singh

1 September 2014 in Cancer & Metabolism
Verified
Journal Article
Open access
PDF file
SSSurendra Shukla
Surendra Shukla
TGTeklab Gebregiworgis
Teklab Gebregiworgis
VPVinee Purohit
Vinee Purohit
NCNina V Chaika
Nina V Chaika
VGVENUGOPAL GUNDA
VENUGOPAL GUNDA
PSPankaj Singh
Pankaj Singh
Aberrant energy metabolism is a hallmark of cancer. To fulfill the increased energy requirements, tumor cells secrete cytokines/factors inducing muscle and fat degradation in cancer patients, a condition known as cancer cachexia. It accounts for nearly 20% of all cancer-related deaths. However, the mechanistic basis of cancer cachexia and therapies targeting cancer cachexia thus far remain elusive. A ketogenic diet, a high-fat and low-carbohydrate diet that elevates circulating levels of ketone bodies (i.e., acetoacetate, β-hydroxybutyrate, and acetone), serves as an alternative energy source. It has also been proposed that a ketogenic diet leads to systemic metabolic changes. Keeping in view the significant role of metabolic alterations in cancer, we hypothesized that a ketogenic diet may diminish glycolytic flux in tumor cells to alleviate cachexia syndrome and, hence, may provide an efficient therapeutic strategy. We observed reduced glycolytic flux in tumor cells upon treatment with ketone bodies. Ketone bodies also diminished glutamine uptake, overall ATP content, and survival in multiple pancreatic cancer cell lines, while inducing apoptosis. A decrease in levels of c-Myc, a metabolic master regulator, and its recruitment on glycolytic gene promoters, was in part responsible for the metabolic phenotype in tumor cells. Ketone body-induced intracellular metabolomic reprogramming in pancreatic cancer cells also leads to a significantly diminished cachexia in cell line models. Our mouse orthotopic xenograft models further confirmed the effect of a ketogenic diet in diminishing tumor growth and cachexia. Thus, our studies demonstrate that the cachectic phenotype is in part due to metabolic alterations in tumor cells, which can be reverted by a ketogenic diet, causing reduced tumor growth and inhibition of muscle and body weight loss.

1 January 2022 in Trends in Immunology
Verified
Journal Article
Closed access
RKRyan J. King
Ryan J. King
PSPankaj Singh
Pankaj Singh
KMKamiya Mehla
Kamiya Mehla

1 August 2020 in Cancer Letters
Verified
Journal Article
Closed access
SSSurendra K. Shukla
Surendra K. Shukla
SMSpas D. Markov
Spas D. Markov
KAKuldeep S. Attri
Kuldeep S. Attri
EVEnza Vernucci
Enza Vernucci
RKRyan J. King
Ryan J. King
KMKamiya Mehla
Kamiya Mehla

10 January 2022 in Oncogene
Verified
Journal Article
Closed access
PDF file
RKRyan J. King
Ryan J. King
SSSurendra K. Shukla
Surendra K. Shukla
CHChunbo He
Chunbo He
EVEnza Vernucci
Enza Vernucci
RAVI THAKURRAVI THAKUR
RAVI THAKUR
PSPankaj Singh
Pankaj Singh

1 January 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KMKamiya Mehla
Kamiya Mehla
PSPankaj Singh
Pankaj Singh
Through metabolic subtyping, metabolic vulnerabilities can be exploited for developing efficacious treatments. A glycolytic subtype indicates poor survival in patients with pancreatic cancer, whereas a cholesterogenic subtype correlates with better outcomes potentially due to more energy expenditure. Personalized medicine holds great promise for improving therapy outcomes by optimally targeting metabolic pathways. See related article by Karasinska et al., p. 135